Latest Breaking News On - Society for immunotherapy of cancer - Page 1 : vimarsana.com

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC

Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.

Iovance Biotherapeutics : 2022 Annual Report

ANNUAL REPORT 2 0 2 2 D E A R S H A R E H O L D E R S : 2022 was a pivotal year for...

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Celularity Data Published in Journal for ImmunoTherapy of

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript

Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06.

Lung Cancer Research Foundation Welcomes New Scientific Advisory Board Members

/PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) has expanded its Scientific Advisory Board (SAB) by five new members. Led by Katerina Politi, PhD,...

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

•   Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology 65th Annual Meeting •   Execution of strategic...

Cidara Therapeutics Provides Corporate Update and Reports

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, April 22, 2024 -- Cidara Therapeutics, Inc. , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate immunotherapies designed to save lives...